Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005164813 | Prostate | Tumor | vesicle localization | 51/3246 | 177/18723 | 1.03e-04 | 9.96e-04 | 51 |
GO:004312315 | Prostate | Tumor | positive regulation of I-kappaB kinase/NF-kappaB signaling | 53/3246 | 186/18723 | 1.04e-04 | 1.00e-03 | 53 |
GO:000020914 | Prostate | Tumor | protein polyubiquitination | 64/3246 | 236/18723 | 1.08e-04 | 1.03e-03 | 64 |
GO:004876213 | Prostate | Tumor | mesenchymal cell differentiation | 64/3246 | 236/18723 | 1.08e-04 | 1.03e-03 | 64 |
GO:000183813 | Prostate | Tumor | embryonic epithelial tube formation | 38/3246 | 121/18723 | 1.09e-04 | 1.03e-03 | 38 |
GO:004666111 | Prostate | Tumor | male sex differentiation | 48/3246 | 165/18723 | 1.25e-04 | 1.16e-03 | 48 |
GO:000636812 | Prostate | Tumor | transcription elongation from RNA polymerase II promoter | 25/3246 | 69/18723 | 1.33e-04 | 1.23e-03 | 25 |
GO:190040717 | Prostate | Tumor | regulation of cellular response to oxidative stress | 30/3246 | 89/18723 | 1.38e-04 | 1.27e-03 | 30 |
GO:005197214 | Prostate | Tumor | regulation of telomerase activity | 19/3246 | 47/18723 | 1.60e-04 | 1.44e-03 | 19 |
GO:007189714 | Prostate | Tumor | DNA biosynthetic process | 51/3246 | 180/18723 | 1.63e-04 | 1.46e-03 | 51 |
GO:006048513 | Prostate | Tumor | mesenchyme development | 75/3246 | 291/18723 | 1.74e-04 | 1.53e-03 | 75 |
GO:000736912 | Prostate | Tumor | gastrulation | 52/3246 | 185/18723 | 1.76e-04 | 1.55e-03 | 52 |
GO:006047912 | Prostate | Tumor | lung cell differentiation | 12/3246 | 24/18723 | 2.47e-04 | 2.08e-03 | 12 |
GO:20006791 | Prostate | Tumor | positive regulation of transcription regulatory region DNA binding | 12/3246 | 24/18723 | 2.47e-04 | 2.08e-03 | 12 |
GO:005109014 | Prostate | Tumor | regulation of DNA-binding transcription factor activity | 105/3246 | 440/18723 | 2.69e-04 | 2.23e-03 | 105 |
GO:000754811 | Prostate | Tumor | sex differentiation | 71/3246 | 276/18723 | 2.70e-04 | 2.24e-03 | 71 |
GO:190313113 | Prostate | Tumor | mononuclear cell differentiation | 102/3246 | 426/18723 | 2.87e-04 | 2.32e-03 | 102 |
GO:005105212 | Prostate | Tumor | regulation of DNA metabolic process | 88/3246 | 359/18723 | 3.23e-04 | 2.59e-03 | 88 |
GO:007207314 | Prostate | Tumor | kidney epithelium development | 40/3246 | 136/18723 | 3.43e-04 | 2.73e-03 | 40 |
GO:004269213 | Prostate | Tumor | muscle cell differentiation | 93/3246 | 384/18723 | 3.45e-04 | 2.73e-03 | 93 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0513218 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
hsa0516718 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0541818 | Breast | Precancer | Fluid shear stress and atherosclerosis | 28/684 | 139/8465 | 4.74e-06 | 6.00e-05 | 4.59e-05 | 28 |
hsa0510018 | Breast | Precancer | Bacterial invasion of epithelial cells | 16/684 | 77/8465 | 3.55e-04 | 2.80e-03 | 2.15e-03 | 16 |
hsa0467018 | Breast | Precancer | Leukocyte transendothelial migration | 20/684 | 114/8465 | 7.26e-04 | 5.33e-03 | 4.09e-03 | 20 |
hsa0520514 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
hsa0452018 | Breast | Precancer | Adherens junction | 17/684 | 93/8465 | 1.11e-03 | 7.57e-03 | 5.80e-03 | 17 |
hsa0516316 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0513219 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
hsa0516719 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0541819 | Breast | Precancer | Fluid shear stress and atherosclerosis | 28/684 | 139/8465 | 4.74e-06 | 6.00e-05 | 4.59e-05 | 28 |
hsa0510019 | Breast | Precancer | Bacterial invasion of epithelial cells | 16/684 | 77/8465 | 3.55e-04 | 2.80e-03 | 2.15e-03 | 16 |
hsa0467019 | Breast | Precancer | Leukocyte transendothelial migration | 20/684 | 114/8465 | 7.26e-04 | 5.33e-03 | 4.09e-03 | 20 |
hsa0520515 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
hsa0452019 | Breast | Precancer | Adherens junction | 17/684 | 93/8465 | 1.11e-03 | 7.57e-03 | 5.80e-03 | 17 |
hsa0516317 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
CTNNB1 | NK | Endometrium | ADJ | GALNT2,PLEKHA5,SEC14L1, etc. | 4.03e-01 | |
CTNNB1 | GDT | Endometrium | AEH | GALNT2,PLEKHA5,SEC14L1, etc. | 2.12e-01 | |
CTNNB1 | NK | Endometrium | AEH | GALNT2,PLEKHA5,SEC14L1, etc. | 1.16e-01 | |
CTNNB1 | GDT | Endometrium | EEC | GALNT2,PLEKHA5,SEC14L1, etc. | 1.23e-01 | |
CTNNB1 | NK | Endometrium | EEC | GALNT2,PLEKHA5,SEC14L1, etc. | 5.56e-02 | |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1499 | CTNNB1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME, DRUG RESISTANCE | | NVP-TNKS656 | | 26224873 |
1499 | CTNNB1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME, DRUG RESISTANCE | | BC21 | | 22224445 |
1499 | CTNNB1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME, DRUG RESISTANCE | | Triciribine | TRICIRIBINE | 26224873 |
1499 | CTNNB1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME, DRUG RESISTANCE | | CEQ508 | | |
1499 | CTNNB1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME, DRUG RESISTANCE | | dexamethasone | DEXAMETHASONE | 26521987 |
1499 | CTNNB1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME, DRUG RESISTANCE | | ANTI-PD-L1 MONOCLONAL ANTIBODY | | 25970248 |
1499 | CTNNB1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME, DRUG RESISTANCE | | EOSIN_Y | EOSIN_Y | 22889313 |
1499 | CTNNB1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME, DRUG RESISTANCE | | (+/-)-HYDNOCARPIN | CHEMBL91638 | 24018191 |
1499 | CTNNB1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME, DRUG RESISTANCE | | ANTI-CTLA-4 MONOCLONAL ANTIBODY | | 25970248 |
1499 | CTNNB1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME, DRUG RESISTANCE | | FLUORESCEIN SODIUM | FLUORESCEIN SODIUM | 22889313 |